A novel mutation site in STAT in a chronic mucocutaneous candidiasis pediatric patient with disseminated cryptococcosis: Case report and review of the literature

Chuan Gan; Yu Nie; Gaihuan Zheng

doi:10.1002/pdi3.58

Pediatric Discovery ›› 2024, Vol. 2 ›› Issue (2) :e58 DOI: 10.1002/pdi3.58

CASE REPORT

A novel mutation site in STAT in a chronic mucocutaneous candidiasis pediatric patient with disseminated cryptococcosis: Case report and review of the literature

Author information +

History +

PDF

Cite this article

Download citation ▾

Chuan Gan, Yu Nie, Gaihuan Zheng. A novel mutation site in STAT in a chronic mucocutaneous candidiasis pediatric patient with disseminated cryptococcosis: Case report and review of the literature. Pediatric Discovery, 2024, 2(2): e58 DOI:10.1002/pdi3.58

登录浏览全文

4963

注册一个新账户忘记密码

References

Publishing order | Descend order by publishing year | Descend order by cited within

[1]	van de Veerdonk FL, Plantinga TS, Hoischen A, et al. STAT1 mutations in autosomal dominant chronic mucocutaneous candidiasis. N Engl J Med. 2011;365(1):54-61.

[2]	Okada S, Puel A, Casanova J, Kobayashi M. Chronic mucocutaneous candidiasis disease associated with inborn errors of IL-17 immunity. Clin Transl Immunol. 2016;5(12):e114.

[3]	Green L, Dolen WK. Chronic candidiasis in children. Curr Allergy Asthma Rep. 2017;17(5):31.

[4]	Lionakis MS. Genetic susceptibility to fungal infections in humans. Curr Fungal Infect Rep. 2012;6(1):11-22.

[5]	Rosenzweig SD, Holland SM. Defects in the interferon-gamma and interleukin-12 pathways. Immunol Rev. 2005;203(1):38-47.

[6]	Liu L, Okada S, Kong XF, et al. Gain-of-function human STAT1 mutations impair IL-17 immunity and underlie chronic mucocutaneous candidiasis. J Exp Med. 2011;208(8):1635-1648.

[7]	Kisand K, Peterson P. Autoimmune polyendocrinopathy candidiasis ectodermal dystrophy and other primary immunodeficiency diseases help to resolve the nature of protective immunity against chronic mucocutaneous candidiasis. Curr Opin Pediatr. 2013;25(6):715-721.

[8]	Puel A, Cypowyj S, Bustamante J, et al. Chronic mucocutaneous candidiasis in humans with inborn errors of interleukin-17 immunity. Science. 2011;332(6025):65-68.

[9]	Olbrich P, Freeman AF. STAT1 and STAT3 mutations: important lessons for clinical immunologists. Expet Rev Clin Immunol. 2018;14(12):1029-1041

[10]	Toubiana J, Okada S, Hiller J, et al. Heterozygous STAT1 gain-of-function mutations underlie an unexpectedly broad clinical phenotype. Blood. 2016;127(25):3154-3164.

[11]	Chambo Filho F, Souza Filho JB, Pignaton CC, Zon I, Fernandes AS, Cardoso LQ. Chronic mucocutaneous candidiasis: a case with exuberant cutaneous horns in nipples. An Bras Dermatol. 2014;89(4):641-644.

[12]	Sampaio EP, Hsu AP, Pechacek J, et al. Signal transducer and activator of transcription 1 (STAT1) gain-of-function mutations and disseminated coccidioidomycosis and histoplasmosis. J Allergy Clin Immunol. 2013;131(6):1624-1634.

[13]	Kumar N, Hanks ME, Chandrasekaran P, et al. Gain-of-function signal transducer and activator of transcription 1 (STAT1) mutation-related primary immunodeficiency is associated with disseminated mucormycosis. J Allergy Clin Immunol. 2014;134(1):236-239.

[14]	Kiykim A, Charbonnier LM, Akcay A, et al. Hematopoietic stem cell transplantation in patients with heterozygous STAT1 gain-of-function mutation. J Clin Immunol. 2019;39(1):37-44.

[15]	Wildbaum G, Shahar E, Katz R, Karin N, Etzioni A, Pollack S. Continuous G-CSF therapy for isolated chronic mucocutaneous candidiasis: complete clinical remission with restoration of IL-17 secretion. J Allergy Clin Immunol. 2013;132(3):761-764.

[16]	van de Veerdonk FL, Koenen HJPM, van der Velden WJFM, van der Meer JWM, Netea MG. Immunotherapy with G-CSF in patients with chronic mucocutaneous candidiasis. Immunol Lett. 2015;167(1):54-56.

[17]	Huppler AR, Bishu S, Gaffen SL. Mucocutaneous candidiasis: the IL-17 pathway and implications for targeted immunotherapy. Arthritis Res Ther. 2012;14(4):217.